Optomed Q1: Investment case intact - Redeye

Redeye maintains its valuation of Optomed after the Q1 report. While there is a temporary revenue weekness due to the strategic decopling from China and a strong focus shift towards the US and Europe, our assumptions stand and our investment case remains intact. We expect the transition and revenue build-up to take 1.5-2 years and see a large growth potential for Optomed's innovative solutions, especially in the USA.

Länk till analysen i sin helhet: https://www.redeye.se/research/841065/optomed-q1-investment-case-intact?utm_source=finwire&utm_medium=RSS